6-K 1 tm228737d1_6k.htm FORM 6-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of March 2022

 

Commission File Number: 001-40850

 

 

 

Exscientia plc

(Translation of registrant’s name into English)

 

 

 

The Schrödinger Building

Oxford Science Park

Oxford OX4 4GE

United Kingdom

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x  Form 20-F    ¨  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

Press Release

 

On March 8, 2021, Exscientia plc issued a press release to announce acceptance of three abstracts for poster presentation at the upcoming American Association for Cancer Research Annual Meeting 2022. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

 

 

 

EXHIBIT INDEX

 

Exhibit
No.
 Description
   
99.1 Press Release, Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022, dated March 8, 2022.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    EXSCIENTIA PLC
       
Date: March 9, 2022 By: /s/ Andrew Hopkins
      Name: Andrew Hopkins
      Title: Chief Executive Officer